Quick Answer
Spero Therapeutics, Inc. reported Operating Income Loss of $6.31 million for the year ending 2025.
- Spero Therapeutics, Inc. showed an increase of +108.6% in Operating Income Loss from 2024 to 2025.
- This data is from Spero Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 11 years of available data (2015 to 2025), Spero Therapeutics, Inc.'s Operating Income Loss has grown by 147.4%.
- Historical annual values: Fiscal year 2025: $6.31 million | Fiscal year 2024: -$73.36 million | Fiscal year 2023: $21.48 million | Fiscal year 2022: -$42.20 million | Fiscal year 2021: -$87.97 million | Fiscal year 2020: -$79.11 million | Fiscal year 2019: -$63.22 million | Fiscal year 2018: -$42.81 million | Fiscal year 2017: -$41.73 million | Fiscal year 2016: -$33.22 million | Fiscal year 2015: -$13.33 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: